What question did this study set out to answer?

To describe the real-world use and safety of olaparib in combination with abiraterone for treating metastatic castration-resistant prostate cancer.

April 15, 2026Open Access

First Real-World Data of Olaparib Combination Treatment with Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer (mCRPC): Descriptive Analysis of 154 Patients Enrolled in the Early Access Program in France

Key Points

To describe the real-world use and safety of olaparib in combination with abiraterone for treating metastatic castration-resistant prostate cancer.
Analyzed data from 154 patients enrolled in an early access program in France.
Assessed patient characteristics in relation to those in the PROpel clinical trial.
Evaluated safety signals and benefit-risk balance of the treatment.
Patient characteristics were similar to those in the PROpel clinical trial.
No new safety signals were identified in this real-world patient cohort.
The overall benefit-risk balance of olaparib remained unchanged.

Abstract

These are the first results describing the real-world use of olaparib in France in prostate cancer. Most patients included in the fEA had generally similar characteristics as the patients randomized in the PROpel clinical trial (NCT03732820) and initiated at the standard dose of 300 mg twice daily. No new safety signals were reported in this real-world patient population. The analyzed data did not modify the benefit-risk balance of olaparib.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Dourthe et al. (Mon,) studied this question.

synapsesocial.com/papers/69df2bece4eeef8a2a6b0dc2 — DOI: https://doi.org/10.1007/s40801-026-00551-z

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

A Topoisomerase IIß-Mediated dsDNA Break Required for Regulated Transcription· 2006 · 842 citations
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer· 2016 · 1,655 citations
Real-world evidence in the treatment of ovarian cancer· 2017 · 379 citations
AMPed up to treat prostate cancer: novel AMPK activators emerge for cancer therapy· 2014 · 6 citations
Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer· 2005 · 208 citations

Authors

Louis Marie Dourthe

Sorbonne Université

Aline Guillot

Université Claude Bernard Lyon 1

Cécile Vassal

Journals

Drugs - Real World Outcomes

Actions

Institutions

Médipole Garonne

AstraZeneca (France)

Société du Canal de Provence

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

First Real-World Data of Olaparib Combination Treatment with Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer (mCRPC): Descriptive Analysis of 154 Patients Enrolled in the Early Access Program in France

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Also consider

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Also consider